cell free dna blood collection tubes  (Streck Laboratories)

Journal: ESMO Open

Article Title: Clinical utility of pleural effusion supernatant cell-free DNA genotyping in previously treated patients with advanced non-small-cell lung cancer and disease progression: a multicenter retrospective study

doi: 10.1016/j.esmoop.2025.106023

Figure Lengend Snippet: Oncoplot depicting the driver and co-occurring mutations detected in pleural effusion cfDNA from 95 treatment-resistant patients. #Indicates a driver mutation not detected by standard-of-care tests. Multi-hit status was assigned only for two or more pathogenic/likely pathogenic variants; EGFR mutations and variants of uncertain significance were not included in the multi-hit category. IO/chemo, immunotherapy/chemotherapy; TKI, tyrosine kinase inhibitor; VAF, variant allele frequency.

Article Snippet: All pleural effusion samples were collected and transported in cfDNA blood collection tubes (Streck, USA).

Techniques: Mutagenesis, Variant Assay

Journal: ESMO Open

Article Title: Clinical utility of pleural effusion supernatant cell-free DNA genotyping in previously treated patients with advanced non-small-cell lung cancer and disease progression: a multicenter retrospective study

doi: 10.1016/j.esmoop.2025.106023

Figure Lengend Snippet: Genomic alterations detected in pleural effusion cfDNA after disease progression on first- or second-generation EGFR-targeted therapy . (A) Oncoplot of 29 patients resistant to first- or second-generation epidermal growth factor receptor (EGFR)-targeted therapy. (B) Sunburst plot depicting these 29 patients’ driver mutations and potential resistant alterations. CNG, copy number gain.

Article Snippet: All pleural effusion samples were collected and transported in cfDNA blood collection tubes (Streck, USA).

Techniques: Biomarker Discovery

Journal: ESMO Open

Article Title: Clinical utility of pleural effusion supernatant cell-free DNA genotyping in previously treated patients with advanced non-small-cell lung cancer and disease progression: a multicenter retrospective study

doi: 10.1016/j.esmoop.2025.106023

Figure Lengend Snippet: Genomic alterations detected in pleural effusion cfDNA after disease progression on first-line or second-line osimertinib . (A) Oncoplot for 14 patients resistant to treatment with first-line osimertinib and 15 patients resistant to second-line osimertinib. (B) Sunburst plot of these patients’ driver mutations and potential resistant alterations. CNG, copy number gain.

Article Snippet: All pleural effusion samples were collected and transported in cfDNA blood collection tubes (Streck, USA).

Techniques: Biomarker Discovery